Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. - Wikidata - wikimedia - TriplyDB

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q33187375

about

A review of arsenic trioxide and acute promyelocytic leukemia Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade Differentiation therapy of leukemia: 3 decades of development.Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia.Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.Arsenic trioxide: safety issues and their management.The treatment of elderly patients with acute myeloid leukemia.Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.Arsenic trioxide in the treatment of haematological malignancies.Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide Physiologic Doses of Ascorbic Acid Increase Arsenic Trioxide Toxicity in Human Jurkat -T Lymphoma Cells ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA Acute promyelocytic leukemia: a model of molecular target based therapy.Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.Emerging new approaches for the treatment of acute promyelocytic leukemia.Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells.Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013 Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.Advances in therapies for acute promyelocytic leukemia.Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.The evolving use of arsenic in pharmacotherapy of malignant disease.Contemporary treatment of APL Fighting against hematological malignancy in China: from unique system to global impact.Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.Role of arsenic trioxide in acute promyelocytic leukemia.Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.Severe Acute Axonal Neuropathy following Treatment with Arsenic Trioxide for Acute Promyelocytic Leukemia: a Case Report.

P2860

Q28087768-63A07666-185E-4AD6-80A1-5EE2B3F77965 Q28539684-60E9DC5E-3FFA-4282-AC27-3C350FA41B38 Q33409795-E04AE373-7619-4006-B9F9-104662DF135E Q33588205-91B4282A-51DA-40D3-A310-42D6799C21B2 Q33956085-00D5CC19-3A53-4753-9D9A-051EE9C8D75A Q34014502-BEF93EE2-AF70-4881-A78F-640ECDBECA59 Q34046794-03B99AFF-5591-46E5-9867-CBCBE5399369 Q34546653-3E25C165-35D1-4825-8A7C-F656A7609EEA Q34548159-91AA9304-0FA0-41EE-8CBC-DB9BE88B2748 Q34588761-36A6BE45-084B-4B0F-8D31-2A51E4EEF089 Q35673578-85E0677B-3C6E-4787-86DE-E1787D11BE32 Q35743980-A221D7AB-6D91-4CC5-9C43-B87E2C087D92 Q35925650-4790D5DA-F0FB-40E2-99C4-C453280A3BAA Q35949253-FC68D563-0563-45A6-8C06-778745DEA9F8 Q36078801-EACB04A5-8786-4E76-8DD7-911E612070BB Q36253262-E5D9EE0F-9B0C-4740-B6D2-DD4690253118 Q36270144-7E8B3B03-F46E-4277-8AA9-F14DE70A6668 Q36303245-810C744A-41CD-49BC-B7F4-A3184000DCFD Q36612619-72F9795B-5F96-4515-A22E-B574AC4ED76A Q36732473-7A656BEF-2F46-4F12-81FC-7F0D5C12310A Q36816685-0401D82F-F083-4B3B-B146-33B70590C00D Q36824250-22D376B3-917A-4780-9E7F-A71FD89ED22B Q37117735-41B1C22C-5BA2-47D4-9BC8-0AF0068230C2 Q37182377-A9A26C11-728A-421F-8F26-808C1C7D8BA9 Q37267500-E2B32A9F-61C7-41FB-931D-F71D47DE52DF Q37565126-FA48626D-9070-445B-9809-1F3043317FB2 Q37628630-DDC53229-792B-4FDB-BAE7-A22654AB46CD Q37712353-A7977CCF-555B-44B9-A828-AE15C46A6836 Q37890950-98BC7885-544A-460A-AE9D-1D578882D66C Q37905921-6BC0250F-F0CA-4FB1-B9CC-5927E2AB0204 Q37929546-738CD60E-7365-4C11-A727-DA0B42890BC7 Q37999067-46668300-2698-4F8C-9E8B-9AB8DA5F5121 Q38089629-DC38C4FF-ADFF-45D3-A421-1C6A66C4158F Q38197074-0645A2DD-1A73-4042-B303-420379A51914 Q38632968-7391E9FD-020D-4105-96EB-F156140A2A1A Q39281476-604F911C-0FD6-408C-8681-52F60C57B82C Q39484903-292B76F2-E804-4FFF-97F5-347E14A7EB7F Q39757466-229ACDBB-1142-4B30-8CB2-9558B08CAAF3 Q40413191-5662600C-B3E5-4FCB-831C-7FBE8D2DCA2F Q40720914-D2A242BA-C88F-4FFF-B709-A66FA7DB5D1B

P2860

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q33187375

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Combined treatment with arseni ...... acute promyelocytic leukemia.

@ast

Combined treatment with arseni ...... acute promyelocytic leukemia.

@en

type

label

Combined treatment with arseni ...... acute promyelocytic leukemia.

@ast

Combined treatment with arseni ...... acute promyelocytic leukemia.

@en

prefLabel

Combined treatment with arseni ...... acute promyelocytic leukemia.

@ast

Combined treatment with arseni ...... acute promyelocytic leukemia.

@en

P1433

Q33187375-2F314346-0E9F-4EA4-AB10-AF733CD2AE11

P1476

Q33187375-A831BBED-3FFF-40DC-BD8A-D485A1F38F28

P2093

Q33187375-05E12C46-2983-4ACE-B270-29587D87E99C

Q33187375-1F179835-ABBF-43D4-A520-8C210CA092D0

Q33187375-23987671-97D6-4D68-8609-FDF8D9E1CEB0

Q33187375-3B18D138-EF1E-43DF-9EE2-D0D7D03CAF6D

Q33187375-4ED377C2-C201-4D22-9B04-65EFF6D04860

Q33187375-5C6A0762-C320-499D-ADBB-C0BE3B23DF54

Q33187375-81381DD5-C77B-4531-B23A-F0C5E51A6BBF

Q33187375-AA21AA85-8322-43FE-B574-0D4C67DED93E

Q33187375-CAF93001-1960-4430-AD4F-BBEE0D2DCE0D

Q33187375-E0C113C2-867D-4FC5-9351-9EE88D0C9267

P304

Q33187375-C63DF089-2612-48EA-8EDD-E8B1A642D83D

P31

Q33187375-32EEC289-324E-4193-8E29-130F63896EE3

P356

Q33187375-9F7D47B6-9E2A-4F88-B282-BD8230ADD839

P407

Q33187375-853808A7-3F37-4625-BFE0-43D8DE05A383

P433

Q33187375-56531897-A672-40E4-B05A-41AF6BCDF095

P478

Q33187375-D4E2D7FB-429D-459A-9D76-8C68E04B1C4F

P50

Q33187375-0B966445-2729-4FD2-BB2C-3335AD6DBB7C

Q33187375-7369B243-851A-453F-8613-03FCFC83DECF

Q33187375-74B8C6B9-338D-451A-8FFE-3608D2A75479

Q33187375-829F1960-4B44-49FE-AABF-27F5C087A1E1

Q33187375-911AB5FC-8EC8-4CFC-AA9D-93D2B896FA20

Q33187375-9B24364C-D97A-4400-A296-A4C5A16B4182

Q33187375-B2ABDE1B-186A-4C22-97AB-0D37629ED993

Q33187375-BD8E920C-7094-4425-9F73-3B77B60CA986

P577

Q33187375-0F81D09C-4B4B-4909-B6FF-33B24FE3F421

P5875

Q33187375-7E82D271-420B-4CD8-9E70-22FA93031954

P698

Q33187375-3E6A10EB-3331-430B-8EBF-BD1594F15C15

P921

Q33187375-FC1D6BB8-BAC0-4FCC-90A3-BA686EBC7C9F

P356

JCO.2003.01.149

P1433

Journal of Clinical Oncology

P1476

Combined treatment with arseni ...... acute promyelocytic leukemia.

@en

P2093

Anne-Laure Taksin

http://www.w3.org/2001/XMLSchema#string

Annick Tibi

http://www.w3.org/2001/XMLSchema#string

Emmanuel Raffoux

http://www.w3.org/2001/XMLSchema#string

Geneviève Lebbé

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Fermand

http://www.w3.org/2001/XMLSchema#string

Jöel Poupon

http://www.w3.org/2001/XMLSchema#string

Marie-Thérèse Daniel

http://www.w3.org/2001/XMLSchema#string

Patricia Cimerman

http://www.w3.org/2001/XMLSchema#string

Philippe Rousselot

http://www.w3.org/2001/XMLSchema#string

Richard Delarue

http://www.w3.org/2001/XMLSchema#string

P304

2326-2334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.01.149

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Christine Chomienne

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10710072

http://www.w3.org/2001/XMLSchema#string

P698

12805334

http://www.w3.org/2001/XMLSchema#string

P921